Ariel Investments LLC Sells 316,614 Shares of Prestige Consumer Healthcare Inc. $PBH

Ariel Investments LLC lessened its holdings in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) by 12.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 2,202,327 shares of the company’s stock after selling 316,614 shares during the quarter. Prestige Consumer Healthcare makes up 2.0% of Ariel Investments LLC’s portfolio, making the stock its 19th biggest position. Ariel Investments LLC owned 4.48% of Prestige Consumer Healthcare worth $175,856,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. UMB Bank n.a. increased its position in Prestige Consumer Healthcare by 81.8% during the 2nd quarter. UMB Bank n.a. now owns 320 shares of the company’s stock valued at $26,000 after purchasing an additional 144 shares during the period. Caitong International Asset Management Co. Ltd lifted its position in shares of Prestige Consumer Healthcare by 312.5% in the 2nd quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after purchasing an additional 250 shares during the period. Maseco LLP bought a new stake in shares of Prestige Consumer Healthcare during the 2nd quarter valued at about $27,000. Geneos Wealth Management Inc. increased its position in shares of Prestige Consumer Healthcare by 92.8% during the first quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock valued at $48,000 after buying an additional 269 shares during the period. Finally, Elevation Point Wealth Partners LLC purchased a new position in shares of Prestige Consumer Healthcare during the second quarter valued at about $46,000. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Analyst Upgrades and Downgrades

PBH has been the subject of several research analyst reports. Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a report on Monday, November 10th. Canaccord Genuity Group decreased their target price on Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating for the company in a research report on Friday, November 7th. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Wednesday, October 8th. Sidoti upgraded Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 price target on the stock in a research report on Wednesday, September 24th. Finally, Jefferies Financial Group reduced their price target on Prestige Consumer Healthcare from $75.00 to $71.00 and set a “hold” rating on the stock in a research note on Monday, October 27th. Four research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $85.33.

Insider Activity at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 719 shares of the firm’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $60.00, for a total transaction of $43,140.00. Following the completion of the transaction, the vice president directly owned 42,329 shares in the company, valued at $2,539,740. This trade represents a 1.67% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 1.40% of the company’s stock.

Prestige Consumer Healthcare Price Performance

PBH stock opened at $59.85 on Wednesday. The company has a debt-to-equity ratio of 0.55, a quick ratio of 2.51 and a current ratio of 3.70. The firm has a 50 day moving average price of $60.92 and a 200-day moving average price of $69.29. Prestige Consumer Healthcare Inc. has a 52-week low of $57.25 and a 52-week high of $90.04. The firm has a market capitalization of $2.88 billion, a price-to-earnings ratio of 14.85, a PEG ratio of 1.89 and a beta of 0.39.

Prestige Consumer Healthcare (NYSE:PBH) last posted its quarterly earnings data on Thursday, November 6th. The company reported $1.07 earnings per share for the quarter, beating analysts’ consensus estimates of $0.97 by $0.10. The company had revenue of $274.11 million during the quarter, compared to analyst estimates of $257.14 million. Prestige Consumer Healthcare had a return on equity of 12.43% and a net margin of 18.09%.The firm’s revenue for the quarter was down 3.4% on a year-over-year basis. During the same quarter last year, the company earned $1.09 EPS. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.580 EPS. Equities research analysts forecast that Prestige Consumer Healthcare Inc. will post 4.5 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.